Clinical trial

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

NCT06841874

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2025-12-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Neoplasmsunresolved

Respiratory Tract Neoplasmsunresolved

Thoracic Neoplasmsunresolved

Neoplasms by Siteunresolved

Neoplasmsunresolved

Lung Diseasesunresolved

Respiratory Tract Diseasesunresolved

Carcinomaunresolved

Bronchogenic Carcinomaunresolved

Non Small Cell Carcinoma of the Lungunresolved

ROS1-positive Non-Small Cell Lung Cancer (NSCLC)unresolved

Interventions

TaletrectinibDRUG · verified · RxNorm: taletrectinib

Sponsors & collaborators

Nuvation Bio Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06841874 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.